5:42 PM
 | 
Dec 29, 2016
 |  BC Week In Review  |  Clinical News  |  Clinical Status

JNJ-4178: Ph IIb OMEGA-1 started

Achillion said Johnson & Johnson began the open-label, international Phase IIb OMEGA-1 trial to evaluate oral JNJ-4178 once daily for 6 or 8 weeks in about 300 patients without cirrhosis. JNJ-4178 comprises 800 mg AL-335 from J&J, 25 mg odalasvir from Achillion and 75 mg Olysio simeprevir. Achillion...

Read the full 221 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >